Vericel (VCEL) Cash from Investing Activities (2010 - 2026)
Vericel (VCEL) reported Cash from Investing Activities of -$4.2 million for Q1 2026, up 72.26% on a YoY basis from -$2.4 million in Q1 2025, and up 74.37% sequentially from -$16.4 million in Q4 2025.
Vericel (VCEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Cash from Investing Activities data on file, last reported at -$4.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 72.26% year-over-year to -$4.2 million; the trailing twelve-month figure through Mar 2026 stood at -$33.0 million (up 51.99% YoY), and the FY2025 full-year result was -$43.9 million, up 44.41% from the prior year.
- Cash from Investing Activities grew to -$4.2 million in Q1 2026, from -$16.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $4.6 million in Q3 2023 to a low of -$25.5 million in Q1 2024.
- A 5-year average of -$9.8 million and a median of -$9.0 million in 2025 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 1252.73% in 2022 and soared 663.01% in 2023, its largest moves.
- Tracing VCEL's Cash from Investing Activities over 5 years: stood at -$21.7 million in 2022, then soared by 62.78% to -$8.1 million in 2023, then slumped by 81.14% to -$14.7 million in 2024, then dropped by 11.87% to -$16.4 million in 2025, then surged by 74.37% to -$4.2 million in 2026.
- Business Quant data shows VCEL's Cash from Investing Activities at -$4.2 million in Q1 2026, -$16.4 million in Q4 2025, and -$3.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Vericel | 2.33 Bn | 2.18 Bn | 49.27 Mn | -4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.20 Mn |
| Mar 31, 2026 | -4.20 Mn |
| Dec 31, 2025 | -16.39 Mn |
| Dec 31, 2025 | -16.39 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Mar 31, 2025 | -15.14 Mn |
| Mar 31, 2025 | -15.14 Mn |
| Dec 31, 2024 | -14.65 Mn |
| Dec 31, 2024 | -14.65 Mn |
| Sep 30, 2024 | -21.21 Mn |
| Sep 30, 2024 | -21.21 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Dec 31, 2023 | -8.09 Mn |